Mary Bolt is recruiting for a Toxicologist to join a multinational clinical-stage research company focused on the development and commercialisation of gene therapies for debilitating disorders based on a next-generation AAV gene therapy platform. This will be at their site based in Stevenage on a permanent basis.
The organisation has a strong reputation for their technical and strategic expertise within the cell and gene therapy market across Europe. They place a strong emphasis on innovation, the ability to make a difference to patients lives and enabling staff to apply their skills whilst developing by collaborating within a multidisciplinary team. They will provide you with promising and exciting research projects in an environment that strongly values your development. Their gene therapy treatment builds upon their own pioneering work and their proprietary AAV capsid which is optimised to effectively transduce human liver cells and thus provide sustainable, high levels of the desired protein.
This role is located in Stevenage, Hertfordshire The site is easily commutable by both train and road having strong rail networks with London and being reachable from the M1, M25 and A1(M).
- They are looking for a a scientifically and operationally strong Toxicologist with sound experience of early Phase translational research to lead CROs and external collaborators to deliver successful IND enabling studies supporting gene therapy programmes.
- You will represent the company and work with external providers such as contract research organisations (CROs) and academic specialty laboratories.
- You will also direct and assess the work of a CRO to produce a high standard of work for ex-vivo and in vivo experiments.
The ideal candidate for this role will have:
- A BSc or above in a relevant biological discipline or equivalent level of professional qualifications, with experience of working in the pharmaceutical industry in a preclinical R&D environment.
- A strong scientific background in Pharmacology and Toxicology to address key pharmacologic scientific questions, advancing projects from pre-clinical to early phase clinical development.
- A strong understanding of and experience with GLP toxicity requirements across different territories (e.g. EU, USA) and an understanding of the necessary preclinical data for a lead candidate to support IND/CTA, coupled with experience of working in cross-functional teams to support pre-IND drug development.
- Experience with in vivo models in multiple species (rodent and non-rodent), as well as correlating in vitro/in situ systems with in vivo models and experience of successfully leading multiple GLP-toxicity studies, including protocol writing, study management and reporting.
- Exceptional analytical and problem-solving skills, with the ability to understand and interpret findings and to develop mitigation strategies for the successful progression of projects.
- Excellent verbal and written communication and computer literacy skills, with the ability to write and present clearly and succinctly for regulatory documents, publication, for internal decision making .
- Effective time management with a commitment to meeting deadlines and appreciation for the impact of timing delays on the overall company's objectives.
Please note that your CV should show exact dates of employment (month and year) and any gaps of a month or more should be explained.
CK Group is an Equal Opportunities employer and welcomes applications from all who meet our selection criteria.
If you do not hear back from us within 5 working days of your application for this role, it means that on this occasion you have not been shortlisted for the next stage of the recruitment campaign. Entitlement to work in the EEA is essential. Please quote reference 46307 in all correspondence.
You must be eligible to work in the UK. Learn more
- Agency: CK Group
- Contact: Mary Bolt
- Phone: 01438 743047
- Reference: 46307
- Posted: 16th August 2019
- Expires: 13th September 2019